In bone metastatic breast cancer, RUNX2 promotes cancer cell survival and growth by activating expression of IHH and interacts with the TGFβ/BMP signal transduction pathway to parathyroid hormone-related protein (PTHrP) [49]. Here, IHH is linked to cancer.